FASN and acute myeloid leukemia: Inhibition of FASN—a central enzyme in both de novo palmitic acid synthesis and protein palmitoylation—using the selective inhibitor TVB-3166 resulted in downregulation of the Akt–S6 signaling axis and reduced expression of the transcription factor Gli1, thereby significantly impairing the survival of AML cells.